|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this study, we analyzed modulatory effects on the cell cycle by viscumTT in three osteosarcoma cell lines with various TP53 statuses.
|
29636527 |
2018 |
|
Osteosarcoma
|
1.000 |
GermlineCausalMutation
|
disease |
ORPHANET |
Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE).
|
8401536 |
1993 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.
|
23315976 |
2013 |
|
Osteosarcoma
|
1.000 |
PosttranslationalModification
|
disease |
BEFREE |
Thus, TP53 rearrangements are the major mechanism of p53 inactivation in osteosarcoma.
|
26672768 |
2016 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Our results suggest that alterations of c-myc, N-myc, and c-fos oncogenes occur in osteosarcomas, in addition to those previously described for the tumor suppressor genes RB and p53.
|
8891902 |
1996 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In those OS cell lines reacting with lowered cell division to p53 or Rb delivery, cytostatics only moderately intensified the transgene effects.
|
15538723 |
2005 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Importantly, MG-63 human osteosarcoma xenograft growth in nude mice was significantly suppressed in vivo through triggering apoptosis and p53 phosphorylation.
|
29323455 |
2018 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Here we looked for novel genes potentially (co)regulated by p53 and NF-κB using integrative genomics screening in human osteosarcoma U2-OS cells irradiated with a high dose (4 and 10 Gy).
|
30419821 |
2018 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
LHGDN |
In this study, 21 cases of low-grade central osteosarcoma were analyzed for mutations of the p53 gene, amplification of the MDM2 gene, and mutations of the H-ras gene using formalin-fixed, paraffin-embedded materials.
|
15310147 |
2004 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Remarkably, 5 of the osteosarcomas having Rb alterations also had p53 mutations.
|
8781571 |
1996 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
The effect of overexpression of p21waf1 on drug sensitivity was studied in an osteosarcoma cell line (SaOs-2) lacking both p53 and functional retinoblastoma protein using a tetracycline (TC)-inducible expression system. p21waf1 expression was barely detectable in SaOS-2 cells incubated in the presence of TC.
|
9187120 |
1997 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
While p53 mutations and MDM2 amplification have been reported to occur in rhabdomyosarcoma and osteogenic sarcoma, the incidence of MDM2 in other pediatric solid tumors is not known.
|
8261417 |
1993 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE).
|
8401536 |
1993 |
|
Osteosarcoma
|
1.000 |
SomaticCausalMutation
|
disease |
ORPHANET |
Rearranged p53 genes were also found in human osteogenic sarcoma cell lines.
|
2823272 |
1987 |
|
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Reduced UV-induced mutations in human osteosarcoma cells stably expressing transfected wild-type p53 cDNA.
|
9461020 |
1998 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Strikingly, the development of osteosarcomas in these mice was greatly accelerated compared with mice lacking p53 only.
|
27550453 |
2016 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
We and others have previously described murine models of osteosarcoma based on osteoblast-restricted Cre:lox deletion of Trp53 (p53) and Rb1 (Rb), resulting in a phenotype most similar to fibroblastic osteosarcoma in humans.
|
23486187 |
2013 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this review, a contemporary summarization of the current status of adenovirus-mediated p53 gene therapy of OS is presented.
|
16751779 |
2006 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Mutations in TP53 and RB are linked to OS predisposition and to the evolution of spontaneous OS.
|
26659571 |
2015 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Germline p53 mutations carry an increased risk of development of breast cancer, soft tissue and osteosarcomas, brain tumors, leukemia and adrenocortical carcinomas.
|
9825943 |
1998 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
To investigate the biological significance of RB and p53 gene inactivations, a wild-type RB or p53 cDNA expression vector regulated by tetracycline was introduced by stable transfection into an osteosarcoma cell line Saos-2, in which both the RB and p53 genes were inactivated.
|
9136982 |
1997 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this study we evaluated the cascade of events determined by etoposide-induced DNA damage in OS cell lines with different p53 status focusing on methylation status and expression of miR-34a that modulate tumor cell growth and cell cycle progression.
|
25490093 |
2014 |
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
The current findings demonstrated compellingly that the TP53 R337H mutation is associated not only with ACT but also with CPC and, to a lesser extent, with osteosarcoma, both of which are core-component tumors of the Li-Fraumeni syndrome.
|
21192060 |
2011 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
RUNX2 levels are inversely linked to loss of p53 (which predisposes to OS) in distinct OS cell lines and osteoblasts.
|
23720736 |
2013 |
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Poly(ADP-ribosyl)ation of p53 by PARP-1 during early apoptosis in osteosarcoma cells also inhibited p53 interaction with its DNA consensus sequence; thus, poly(ADP-ribosyl)ation may represent a novel means for regulating transcriptional activation by p53 in vivo.
|
11494111 |
2001 |